{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:33:58Z","timestamp":1794454438221,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Glyde Study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glycogen storage disease type Ib (GSD Ib) is a severe disorder of carbohydrate metabolism due to bi-allelic variants in <jats:italic>SLC37A4<\/jats:italic>. It is associated with neutropaenia and neutrophil dysfunction, which has recently been attributed to the accumulation of 1,5-anhydroglucitol-6-phosphate (1,5AG6P) within neutrophils. Treatment with sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as empagliflozin, is a novel therapy that reduces 1,5-anhydroglucitol (1,5AG) in plasma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We report our experience in treating 8 paediatric GSD Ib patients with empagliflozin with a cumulative treatment time greater than 12\u00a0years. Treatment with a median dose of 5\u00a0mg (0.22\u00a0mg\/kg height weight) of empagliflozin resulted in improvement in bowel health, growth, and laboratory parameters. Plasma 1,5AG levels reduced by a median of 78%. Baseline 1,5AG levels in our cohort were higher than in adult patients with GSD Ib. Hypoglycaemia on empagliflozin treatment occurred in 50% of our cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We report the largest single centre cohort of GSD Ib patients treated with empagliflozin to date. Treatment with SGLT2 inhibitors is a novel and favourable treatment option for neutropaenia and neutrophil dysfunction in GSD Ib. We suggest a low starting dose of empagliflozin with careful titration due to the risk of hypoglycaemia. The interpretation of 1,5AG levels and their role in treatment monitoring is yet to be established, and requires ongoing research.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02345-2","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:04:04Z","timestamp":1652353444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0352-9482","authenticated-orcid":false,"given":"Rebecca K.","family":"Halligan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Neil","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen R.","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2345_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1566524024605798","volume":"2","author":"JY Chou","year":"2002","unstructured":"Chou JY, Matern D, Mansfield BC, Chen YT. Type 1 glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med. 2002;2:121\u201343.","journal-title":"Curr Mol Med"},{"key":"2345_CR2","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1038\/gim.2014.128","volume":"16","author":"PS Kishnani","year":"2014","unstructured":"Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, et al. Diagnosis and management of glycogen storage disease type 1: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014;16:e11.","journal-title":"Genet Med"},{"key":"2345_CR3","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1007\/BF02680007","volume":"161","author":"JP Rake","year":"2002","unstructured":"Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GPA. Guidelines for management of glycogen storage disease type 1\u2014European Study on Glycogen Storage Disease Type 1 (ESGD 1). Eur J Pediatr. 2002;161:S112\u20139.","journal-title":"Eur J Pediatr"},{"key":"2345_CR4","first-page":"S120","volume":"161","author":"G Visser","year":"2002","unstructured":"Visser G, Rake JP, Labrune P, Leonard JV, Moses S, Ullrich K, et al. Consensus guidelines for management of glycogen storage disease type 1b\u2014European Study on Glycogen Storage Disease Type 1. Eur J Pediatr. 2002;161:S120\u20133.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"2345_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1067\/mpd.2000.105232","volume":"137","author":"G Visser","year":"2000","unstructured":"Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European Study on Glycogen Storage Disease Type 1. J Pediatr. 2000;137(2):187\u201391.","journal-title":"J Pediatr"},{"issue":"1","key":"2345_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmd2.12200","volume":"59","author":"R Halligan","year":"2021","unstructured":"Halligan R, White FJ, Schwahn B, Stepien KM, Kamarus Jaman N, McSweeney M, et al. The natural history of glycogen storage disease type Ib in England: a multisite survey. JIMD Rep. 2021;59(1):52\u20139.","journal-title":"JIMD Rep"},{"key":"2345_CR7","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s00431-002-1004-y","volume":"161","author":"P Labrune","year":"2002","unstructured":"Labrune P. Glycogen storage disease type I: indications for liver and\/or kidney transplantation. Eur J Pediatr. 2002;161:S53\u20135.","journal-title":"Eur J Pediatr"},{"key":"2345_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1023\/A:1005544117285","volume":"22","author":"L Faivre","year":"1999","unstructured":"Faivre L, Houssin D, Valayer J, Brouard J, Hadchouel M, Bernard O. Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia. J Inher Metab Dis. 1999;22:723\u201332.","journal-title":"J Inher Metab Dis"},{"key":"2345_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-9-47","volume":"9","author":"SJB Boers","year":"2014","unstructured":"Boers SJB, Visser G, Smit PGPA, Fuchs SA. Liver transplantation in glycogen storage disease type I. Orphanet J Rare Dis. 2014;9:47.","journal-title":"Orphanet J Rare Dis"},{"key":"2345_CR10","volume-title":"JIMD reports","author":"A Sechi","year":"2013","unstructured":"Sechi A, Deroma L, Paci S, Lapolla A, Carubbi F, Burlina A, et al. Quality of life in adults with glycogen storage disease type I: results of a multicenter Italian study. In: Zschocke J, Gibson K, Brown G, Morava E, Peters V, editors., et al., JIMD reports, vol. 14. Berlin: Springer; 2013."},{"issue":"1","key":"2345_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13023-021-02006-w","volume":"16","author":"SF Garbade","year":"2021","unstructured":"Garbade SF, Ederer V, Burgard P, Wendel U, Spiekerkoetter U, Haas D, Grunert SC. Impact of glycogen storage disease type I on adult daily life: a survey. Orphanet J Rare Dis. 2021;16(1):371.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2345_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/jimd.12178","volume":"43","author":"F Peeks","year":"2020","unstructured":"Peeks F, Boonstra WF, de Baere L, Caroe C, Casswall T, Cohen D, et al. Research priorities for liver glycogen storage disease: an international priority setting partnership with the James Lind Alliance. J Inherit Metab Dis. 2020;43(2):279\u201389.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2345_CR13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1073\/pnas.1816143116","volume":"116","author":"M Veiga-da-Cunha","year":"2019","unstructured":"Veiga-da-Cunha M, Chevalier N, Stephenne X, Defour JP, Paczia N, Ferster A, et al. Failure to eliminate a phosphorylated glucose analog leads to neutropaenia in patients with G6PT and G6PC3 deficiency. PNAS. 2019;116(4):1241\u201350.","journal-title":"PNAS"},{"issue":"9","key":"2345_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood.2019004465","volume":"136","author":"SB Wortmann","year":"2020","unstructured":"Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, et al. Treating neutropaenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood. 2020;136(9):1033\u201343.","journal-title":"Blood"},{"key":"2345_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","volume":"47","author":"A Rossi","year":"2021","unstructured":"Rossi A, Miele E, Fecarotta S, Veiga-de-Cunha M, Martinelli M, Mollica C, et al. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. Ital J Pediatr. 2021;47:149.","journal-title":"Ital J Pediatr"},{"key":"2345_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13023-020-01503-8","volume":"15","author":"SC Grunert","year":"2020","unstructured":"Grunert SC, Elling R, Maag B, Wortmann SB, Derks TGJ, Hannibal L, et al. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. Orphanet J Rare Dis. 2020;15:218.","journal-title":"Orphanet J Rare Dis"},{"key":"2345_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/ped.14629","volume":"63","author":"M Mikami","year":"2021","unstructured":"Mikami M, Arai A, Mizumoto H. Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib. Pediatr Int. 2021;63:1394\u20136.","journal-title":"Pediatr Int"},{"issue":"178","key":"2345_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0022-1759(94)00247-T","volume":"13","author":"SJ Vowells","year":"1995","unstructured":"Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods. 1995;13(178):89\u201397.","journal-title":"J Immunol Methods"},{"issue":"1","key":"2345_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clim.2008.11.003","volume":"131","author":"KD Stone","year":"2009","unstructured":"Stone KD, Feldman HA, Huisman C, Howlett C, Jabara HH, Bonilla FA. Analysis of in vitro lymphocyte proliferation as a screening tool for cellular immunodeficiency. Clin Immunol. 2009;131(1):41\u20139.","journal-title":"Clin Immunol"},{"issue":"8","key":"2345_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ibd.20867","volume":"15","author":"D Turner","year":"2009","unstructured":"Turner D, Hyams J, Markowitz J, Lerer T, Mack DR, Evans J, et al. Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis. 2009;15(8):1218\u201323.","journal-title":"Inflamm Bowel Dis"},{"key":"2345_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08880018.2018.1440675","volume":"35","author":"AM Li","year":"2018","unstructured":"Li AM, Thyagu S, Maze D, Scheiber R, Sirrs S, Stockler-Ipsiroglu S, et al. Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukaemia and with shortened telomere length. Pediatr Hematol Oncol. 2018;35:45\u201351.","journal-title":"Pediatr Hematol Oncol"},{"key":"2345_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.clinbiochem.2013.06.003","volume":"46","author":"M Ouchi","year":"2013","unstructured":"Ouchi M, Oba K, Aoyama J, Watanabe K, Ishii K, Yano H, et al. Serum uric acid in relation to serum 1,5-anhydroglucitol levels in patients with and without type 2 diabetes mellitus. Clin Biochem. 2013;46:1436\u201341.","journal-title":"Clin Biochem"},{"key":"2345_CR23","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0140-6736(96)90672-8","volume":"347","author":"T Yamanouchi","year":"1996","unstructured":"Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. The Lancet. 1996;347:1514\u20138.","journal-title":"The Lancet"},{"issue":"4","key":"2345_CR24","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1399-5448.2007.00228.x","volume":"8","author":"TM Nguyen","year":"2007","unstructured":"Nguyen TM, Rodriguez LM, Mason KJ, Heptulla RA. Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes. 2007;8(4):214\u20139.","journal-title":"Pediatr Diabetes"},{"key":"2345_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cca.2015.11.010","volume":"452","author":"D Fortuna","year":"2016","unstructured":"Fortuna D, McCloskey LJ, Stickle DF. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol. Clin Chim Acta. 2016;452:138\u201341.","journal-title":"Clin Chim Acta"},{"key":"2345_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3389\/fped.2020.00591","volume":"8","author":"B Aoun","year":"2020","unstructured":"Aoun B, Sanjad S, Degheili JA, Barhoum A, Bassyouni A, Karam PE. Kidney and metabolic phenotypes in glycogen storage disease type-I patients. Front Pediatr. 2020;8:591. https:\/\/doi.org\/10.3389\/fped.2020.00591.","journal-title":"Front Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02345-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:20:07Z","timestamp":1652354407000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2345"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02345-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed verbal consent for the off-label use of empagliflozin was obtained from the parents of our patients prior to treatment commencement. This is a retrospective collection of anonymized data collected during routine patient care which, in line with the declaration of Helsinki, neither individual patients consents nor formal research ethics committee approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}